We leverage synthetic biomimetic environments to harness cell function
StemBond Technologies is redefining the potential of cell culture with advanced materials science.
By providing precise, mechanically tuned cell culture environments with our proprietary platform technology, we can enhance cell function for therapeutics or mimic disease for target discovery.
About Us
Cambridge University Spin-Out
StemBond Technologies aims to leverage advances made in controlling cell fate and function at the Stem Cell Institute for our partners and future cell products. We are based in the Stem Cell Institute, Cambridge, UK.
Partnerships
The StemBond platform can be mechanically personalised to support an array of vital cell types. We are looking for partners in need of defined cell culture substrates for improved cell function.
Technology: StemBond Hydrogels
Our proprietary hydrogel tissue culture platform delivers the benefits of 3D culture with 2D scalability. With the potential to be GMP compliant and transplantable, StemBond has the capacity to redefine the therapeutic potential of ex vivo cell culture.
Higher-quality cell products
Our platform modulates cell signalling through precise mechanical control of cell culture environments. This is an immensely powerful tool for preserving and enhancing cell function outside of the body.
Our Team
Dr Andrew C. Hodgson
Co-Founder CEO & Director
Prof. Kevin Chalut
Co-Founder & Director
Dr Miguel Forte
Executive Chair
Dr Jason Mellad
Director and Investor
Dr Robert Preti
Director
Upcoming Events:
News
Collaborations
Contact us to discuss how our platforms could work for you.
We can design pilot studies through to integration and novel applications.
Key Publications
Our cell culture platform has been adopted by leading research groups
Investors, Partners and Affiliations
